The study will compare the prodisc C Vivo and prodisc C SK cervical discs with the Mobi-C, which received FDA approval in 2013.
The two-to-one randomized trial is enrolling patients with neck and arm pain who have not had a previous spine surgery.
The Mobi-C device will be used as a control to determine the safety and efficacy of the trial discs to treat cervical disc disease in patients unresponsive to nonoperative treatment at two levels.
More articles on devices:
Stryker ranks No. 8 in Fortune’s 100 best workplaces
Wuhan neurosurgeon, hospital director dies from coronavirus, death toll rises to 1,800+
Medtronic reports spine revenue up 3%, hurt by low BMP sales: 7 things to know
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.